MedTrace Logo

Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study

NCT02714894 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2022-06-03

No results posted yet for this study

Summary

The purpose of this study is to investigate the relationship between glutamate and related brain chemicals and treatment response to clozapine in patients with treatment-resistant schizophrenia.

Conditions

Interventions

DRUG

Clozapine

Patient participants will be starting clozapine as part of their clinical care.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Ariel Graff, MD, PhD · Centre for Addiction and Mental Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2022-07-30
Completion
2022-07-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02714894 on ClinicalTrials.gov